Topics:

• The Basis: Immunological Pathways of Type 2 Inflammation
• Biologicals for Type 2-Mediated Diseases
• Treating Type 2 Inflammation in Airways
• Type 2 Inflammation and Skin Disorders
• Inflammation in Food
• Type 2 Inflammation in Rare Diseases

Clinical corners:

• What Drives the Direction of Treatment Choice in Asthma and CRSwNP?
• Safety of Anti-Type 2 Biologicals
• Diagnostic Approach to High Blood Eosinophil Count

Format of the different activities:

• Sessions: 2-3 lectures around the addressed main topic
• Workshops: The topic will be developed around a clinical case answered by the attendees
• Posters sessions: defended by the delegates
• Oral presentations: defended by the delegates

Attendees will be able:

• to improve their knowledge of immunological basis of local and systemic type 2 inflammation
• to explore the pathogenic and clinical significance of type 2 cytokines in different eosinophil-associated diseases
• to understand the rationale for biologicals’ use in type 2 eosinophil-associated diseases
• to learn how to identify patients affected by different forms of hypereosinophilic syndrome and how to implement the use of biologicals in this condition
• to combine the immunological knowledge with the clinical data collected regarding the safety profile of biologicals targeting eosinophils and type 2 cytokines
• to expand their knowledge about the role of eosinophils in adverse drug reactions
• to actively participate in “clinical corners” by sharing their personal experience in hot topic issues related to type 2 diseases  Attendees will be able:
• to improve their knowledge of immunological basis of local and systemica type 2 inflammation
• to explore the pathogenic and clinical significance of type 2 cytokines in different eosinophil-associated diseases
• to understand the rationale for biologicals’ use in type 2 eosinophil-associated diseases
• to learn how to identify patients affected by different forms of hypereosinophilic syndrome and how to implement the use of biologicals in this condition
• to combine the immunological knowledge with the clinical data collected regarding the safety profile of biologicals targeting eosinophils and type 2 cytokines
• to expand their knowledge about the role of eosinophils in adverse drug reactions
• to actively participate in “clinical corners” by sharing their personal experience in hot topic issues related to type 2 diseases